AbCellera Biologics ( (ABCL) ) has shared an update.
AbCellera reported its Q3 2024 financial results, highlighting a strategic expansion with Eli Lilly for antibody discovery in key therapeutic areas. Despite a slight dip in revenue to $6.5 million, the company bolstered its R&D efforts with increased expenses of $41 million, aiming to advance its internal pipeline. AbCellera achieved 95 partner-initiated program starts and advanced 14 molecules to clinical stages, reflecting robust growth and a focus on future clinical trials.
See more insights into ABCL stock on TipRanks’ Stock Analysis page.
